Toggle Nav
Close
  • Menu
  • Setting

Anti-NaPi2b/SLC34A2 Antibody (Lifastuzumab)

Catalog No.
F1444
Anti-NaPi2b/SLC34A2 Antibody (Lifastuzumab)
Grouped product items
SizePriceStock Qty
100ug
Please inquire
Ship with 3-5 days
1mg
Please inquire
Ship with 3-5 days
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Lifastuzumab is a humanizedNaPi2bMonoclonal antibody (IgG1 type). Lifastuzumab can be usedADC Linker With monomethylauristatin E (MMAE) coupling to form the antibody-drug conjugate (ADC) Lifastuzumab vedotin (DNIB0600A) with anti-cancer activity.

Quality Control

Quality Control & DataSheet

View current batch:
 

M.Wt

145.66 kDa

Shipping

Dry ice

Cas No.

1615697-16-9

Storage

-80°C

Expiration Date

2 years

Form

Liquid

Concentration

See label

Reconstitution

For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.

Host

CHO

Alternative Names

Lifastuzumab

Buffer System

100 mM Pro 20 mM Arg pH 5.0. No preservative!

Target Accession

O95436

Reactivity

Human

Conjugation

Unconjugated

Clonality

Monoclonal

Purification

Protein A

Isotype

IgG1

Application

ELISA, FACS, Kinetics, Functional assay, Animal Model

Biological Activity

Human NaPi2b HEK293 Cell Line were stained with Anti-NaPi2b / SLC34A2 Reference Antibody (lifastuzumab)and negative control protein respectively, washed and then followed by PE and analyzed with FACS, The EC50 is 1.585 ug/mL.

Target

NaPi2b / SLC34A2

Note

Please avoid freeze-thaw cycles.